1. At a Glance
Alkem Labs isn’t just another pharma name — it’s the #1 anti-infective player in India and the 5th largest domestic formulations company with a 4.1% market share. FY25 clocked ₹13,304 Cr in sales and ₹2,333 Cr in PAT, giving it an ROE of 19.4% and a comfortable ROCE of 20.4%. With a P/E of ~27x, the market’s saying: “You’re not Sun Pharma yet, but you’re not some small-cap API shop either.” Dividend payout? A healthy 37%, which means shareholders get more than just the joy of reading annual reports.
2. Introduction
In a country where fevers and infections spread faster than stock market rumours, Alkem has built its fortress on antibiotics. But it’s not sitting still — the company’s chronic therapy push in neurology, cardiology, and diabetology is aimed at keeping revenue steady even when monsoon fevers fade.
Q1 FY26 was a clean 11% YoY sales growth story with a 20% OPM and ₹668 Cr net profit (+19.9% YoY), boosted by both domestic and international markets. They also announced a 51% stake in a new Saudi Arabia subsidiary — expanding beyond India’s crowded pharma playground.
The growth challenge? 5-year sales CAGR is only 9%, slower than some peers. But a 10-year profit CAGR of 20% says Alkem knows how to fatten the bottom line even in a slow-growth top line world.
3. Business Model (WTF Do They Even Do?)
Alkem makes and sells:
- Formulations – Tablets, capsules, injectables across anti-infectives, GI, pain management, vitamins, minerals, chronic therapies.
- Nutraceuticals – Because sometimes you just need a vitamin pill in shiny packaging.
- APIs – Not their core, but enough to keep control over costs
